Blood cancer journal · 2026
Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ghesquières Hervé, Drouet Youenn, Slager Susan L, Morschhauser Franck, Julia Edith, Galimberti Sara, Robinson Dennis, Larson Melissa C, Testard Quentin, Tesson Bruno, Deleuze Jean-François, Boland Anne, Thomas Emilie, Lasset Christine, Novak Anne J, Xerri Luc, Luminari Stefano, Verney Aurelie, Laurent Camille, Rimsza Lisa M, Habermann Thomas M, Federico Massimo, Link Brian K, Salles Gilles, Cerhan James R
Аннотация
Genome-wide association studies (GWAS) have identified germline genetic variants for follicular lymphoma (FL) susceptibility. We conducted a GWAS of prognosis in FL patients to identify genetic predictors of event-free survival (EFS) as well as failure within the first 24 months after treatment initiation (EFS24) using patients treated with rituximab-based immunochemotherapy from three clinical trials and one prospective observational study (N = 1054). Statistical approaches consisted of a pooled GWAS of the four cohorts and a leave-one-cohort-out (LOCO) strategy to identify robust findings that replicated across the four cohorts. The top SNPs for EFS and EFS24 were marked by rs72625024 at 3q27.3 near FETUB and HRG (P = 9.37 × 10-8) and rs114695031 at 14q32.13 near TCL6 (P = 1.93 × 10-8), respectively. These two loci, which were discovered and validated in all 4 LOCO rounds, map near long-non-coding RNAs with putative tumor suppressor functions. Our results pinpoint potential novel biology and the contribution of host genetics to prognosis in FL.